The goal of this clinical research study is to assess whether the combination of BP1001 and cytarabine provides greater efficacy (Complete Remission [CR], Complete Remission with incomplete hematologic recovery [CRi], Complete Remission with incomplete platelet recovery [CRp]) than cytarabine alone (by historical comparison) in participants with AML that cannot or elect not to be treated with more intensive chemotherapy.

In this protocol, we plan to prospectively recruit subjects with chronic kidney disease or end stage kidney disease on dialysis. We will obtain stool, blood, urine (if possible), and peritoneal fluid (if on peritoneal dialysis) from the subjects on a regular basis and we will correlate whether the microbiome in these biospecimens are associated with and/or predictive of bacteremia and other complications in chronic kidney disease and end stage kidney disease.

This is a retrospective and prospective study to study the use of MRI prostate imaging and other patient characteristics such as PSA and commercially available assays and its accuracy in predicting the grade and location of prostate cancer during prostate needle biopsy as well as radical prostatectomy for men going onto surgery. 

Patients with various forms of heart and lung disease exhibit varying degrees of pulmonary hypertension, pulmonary vascular remodeling, and right ventricular dysfunction. The genetic, molecular, and cellular processes driving these phenomena are not well understood.

This research study is being conducted by Dr. Robbyn Sockolow, MD, the director of Pediatric Gastroenterology and Nutrition at Weill Cornell Medical College (WCM) and Komansky Children’s Hospital, and Dr. David Artis, PhD, the director of the Jill Roberts Institute for IBD at WCM. Their teams are looking for pediatric patients who are undergoing a colonoscopy or intestinal surgery.

Why is the study being done?
We are learning about the factors underlying inflammatory bowel disease with the hope that we may improve the care of pediatric patients. 

The Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF-PRO)  aims to:

• Collect information regarding the natural history of IPF and healthcare interactions
• Describe quality of life of IPF participants with patient reported questionnaires
• Assess the methods of treatment of participants
• Collect blood specimens for future research projects

Low Risk Main Randomized Trial has been closed to enrollment. 
    
Bicuspid Registry - Currently Enrolling: 

To assess the safety and effectiveness of the SAPIEN 3 Edwards Valve in patients who are low risk for open heart surgery and have been diagnosed with severe aortic stenosis and a bicuspid aortic valve can be enrolled into a non-randomized registry and undergo a TAVR procedure. 

This trial is open to newly diagnosed Stage I-III breast cancer patients with an indication for post-operative radiotherapy after neo-adjuvant chemotherapy and surgery.

Patients undergoing primary systemic therapy, followed by surgery often receive post-operative radiation. While the targets treated post-operatively vary and depend on the initial and post-surgical stage, patients generally undergo 6-7 weeks of daily (Monday to Friday) post-operative radiation.

The purpose of this study is to look at specific types of immune regulatory cells in the body. These cells work with the immune system. The immune system helps your body fight infections. We would like to be able to see if abnormalities in these cells might be the cause of your ITP and may determine how you might respond to certain treatments.